Redeye adjusts its estimates and fair value range for Xbrane Biopharma following its Q3 2023 report, which prompted a substantial decline in the share price. The anticipated near-term deals for the Ximluci and Xdivane projects should however alleviate these concerns and improve the company’s financial prospects.

https://www.redeye.se/research/965807/xbrane-biopharma-q3-2023-standing-before-a-critical-year?utm_source=finwire&utm_medium=RSS

Redeye